Change of Adviser
https://www.motifbio.com/wp-content/uploads/2019/10/MTFB-Change-of-Adviser-03.10.19.pdf
Conditional Placing to Raise Gross Proceeds of £600,000 (US$0.73 million)
https://www.motifbio.com/wp-content/uploads/2019/10/MTFB-Conditional-Placing-02.10.19.pdf
Half-Year 2019 Financial Results, Operational Progress and Proposed Initiatives
https://www.motifbio.com/wp-content/uploads/2019/09/MTFB-Interim-Release-Results-Final.pdf
Holding(s) in Company
https://www.motifbio.com/wp-content/uploads/2019/09/MTFB-TR-1-Sand-Grove-Capital-Management-LLP-04.09.19.pdf
Motif Bio and Hercules Capital Amend Loan and Security Agreement
https://www.motifbio.com/wp-content/uploads/2019/08/MTFB-Motif-Bio-and-Hercules-Capital-Amend-Loan-and-Security-Agreement-02.09.19.pdf
NIH to Evaluate Iclaprim Activity against Listeria
https://www.motifbio.com/wp-content/uploads/2019/08/20190819_Listeria-NIH_MTFB_PR_FINAL.pdf
Motif Bio and Hercules Capital Amend Loan and Security Agreement
https://www.motifbio.com/wp-content/uploads/2019/07/MTFB-Hercules-RNS-01.08.19.pdf
Motif Bio Confirms Meeting Date with U.S. FDA regarding Iclaprim
https://www.motifbio.com/wp-content/uploads/2019/07/20190726_FINAL_MTFB-PR_FDA-Type-B-mtg-date.pdf
Motif Bio Confirms Receipt of Deficiency Notice from Nasdaq
https://www.motifbio.com/wp-content/uploads/2019/07/Motif-Bio-Confirms-Receipt-of-Deficiency-Notice-from-Nasdaq-26.07.19.pdf
Motif Bio Announces Receipt of Deficiency Notice from Nasdaq
https://www.motifbio.com/wp-content/uploads/2019/07/20190719_FINAL-PR-MTFB_Nasdaq-Deficiency-Letter.pdf
Holding(s) in Company
https://www.motifbio.com/wp-content/uploads/2019/07/MTFB-TR-1-HSBC-Holdings-PLC-18.07.19.pdf
Holding(s) in Company
https://www.motifbio.com/wp-content/uploads/2019/06/MTFB-TR-1-HSBC-Holdings-PLC-28.06.19.pdf
Motif Bio Presents New Iclaprim Data at ASM Microbe 2019
https://www.motifbio.com/wp-content/uploads/2019/06/20190624_MTFB-ASM-Microbe-data-PR.pdf
Holding(s) in Company
https://www.motifbio.com/wp-content/uploads/2019/06/MTFB-TR-1-HSBC-Holdings-PLC-19.06.19.pdf
Holding(s) in Company
https://www.motifbio.com/wp-content/uploads/2019/06/MTFB-TR-1-SAND-GROVE-CAPITAL-MANAGEMENT-LLP-18.06.19.pdf
Holding(s) in Company
https://www.motifbio.com/wp-content/uploads/2019/06/MTFB-TR-1-Amphion-Innovations-plc-14.05.19.pdf
Holding(s) in Company
https://www.motifbio.com/wp-content/uploads/2019/06/TR1-Form-10062019-Issuer.pdf
Motif Bio Announces Path Forward for Iclaprim following Receipt of FDA Meeting Minutes
https://www.motifbio.com/wp-content/uploads/2019/06/MTFB-FDA-meeting-minutes-06.06.19.pdf
Results of Annual General Meeting
https://www.motifbio.com/wp-content/uploads/2019/05/20190531_MTFB-Result-of-AGM-FINAL.pdf
Holding(s) in Company
https://www.motifbio.com/wp-content/uploads/2019/05/AMP-31-May-2019-notifications-major-interests.pdf
Holding(s) in Company
https://www.motifbio.com/wp-content/uploads/2019/05/TR1-Form-28052019-Issuer.pdf
AGM Statement
https://www.motifbio.com/wp-content/uploads/2019/05/MTFB-AGM-Statement-22.05.19.pdf
Motif Bio to Evaluate Orphan Disease Opportunity for Iclaprim in Ophthalmology
https://www.motifbio.com/wp-content/uploads/2019/05/MTFB-Chorioretinitis-in-vitro-study-22.05.19-FINAL.pdf
Motif Bio to Present Iclaprim Data at ASM Microbe 2019
https://www.motifbio.com/wp-content/uploads/2019/05/MTFB-ASM-2019-Curtain-Raiser-21.05.19.pdf
Holding(s) in Company
https://www.motifbio.com/wp-content/uploads/2019/05/MTFB-TR-1-Amphion-Innovations-plc-20.05.19.pdf
Motif Bio meeting with U.S. FDA held as planned
https://www.motifbio.com/wp-content/uploads/2019/05/MTFB-FDA-Mtg-confirmation-03.05.19.pdf
Motif Bio Signs Agreement with Lamellar Biomedical
https://www.motifbio.com/wp-content/uploads/2019/04/20190501_MTFB-PR_Lamellar.pdf
Notice of Annual General Meeting
https://www.motifbio.com/wp-content/uploads/2019/04/MTFB-Posting-of-UK-ARA-_Notice-of-AGM_Final.pdf
Motif Bio Announces Appointment of Andrew Powell to Board of Directors
https://www.motifbio.com/wp-content/uploads/2019/04/MTFB-PR-New-BoD-mbr-FINAL-26.04.19.pdf
Motif Bio Presents New Iclaprim Data at ECCMID 2019
https://www.motifbio.com/wp-content/uploads/2019/04/20190416_MTFB_PR_ECCMID-data.pdf
Motif Bio Reports Fiscal Year 2018 Results
https://www.motifbio.com/wp-content/uploads/2019/04/MTFB-Year-End-Financial-Results-RNS-15.04.19.pdf
Motif Bio to Present Iclaprim Data at ECCMID 2019
https://www.motifbio.com/wp-content/uploads/2019/04/20190404_MTFB_PR_ECCMID-Curtain-raiser_FINAL.pdf
Holding(s) in Company
https://www.motifbio.com/wp-content/uploads/2019/04/MTFB-TR-1-HSBC-Bank-plc-02.04.19.pdf
Holding(s) in Company
https://www.motifbio.com/wp-content/uploads/2019/04/MTFB-TR-1-SAND-GROVE-CAPITAL-MANAGEMENT-LLP-01.04.19.pdf
Holding(s) in Company
https://www.motifbio.com/wp-content/uploads/2019/04/Motif-Bio-Plc-01042019-1-april.pdf
Motif Bio Raises £2.7m (US$3.55m)
https://www.motifbio.com/wp-content/uploads/2019/03/MTFB-Motif-Bio-Raises-£2.7m-US3.55m-26.03.19.pdf
Proposed Equity Fundraise
https://www.motifbio.com/wp-content/uploads/2019/03/MTFB-Proposed-Equity-Fundraise-25.03.19.pdf
Motif Bio Granted Meeting with U.S. FDA regarding Iclaprim
https://www.motifbio.com/wp-content/uploads/2019/03/20190320_PR-MTFB-FDA-meeting-granted.pdf
Holding(s) in Company
https://www.motifbio.com/wp-content/uploads/2019/03/Notifications-of-Major-Interest.pdf
Motif Bio Announces Appointment of Bruce Williams as Interim Chairman and Resignation of Richard Morgan from the Board
https://www.motifbio.com/wp-content/uploads/2019/03/20190318-MTFB-PR-Chairman-FINAL.pdf
This website uses cookies to improve your experience. You can opt-out if you wish.
Accept Read More Privacy & Cookies Policy
